Last updated on November 2015

B55: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy


Brief description of study

B55: A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Detailed Study Description

The purpose of this study is to find out if the addition of olaparib after the usual care of chemotherapy, surgery, and radiation for breast cancer reduces the risk of breast cancer from coming back.

Clinical Study Identifier: TX141814

Find a site near you

Start Over

AMITA Health

3040 Salt Creek Lane Arlington Heights, IL USA
  Connect »